HOME >> BIOLOGY >> NEWS
Preventing graft-versus-host disease disease after bone marrow transplant -- without toxicity

organ failure and death. It strikes some 30-60 percent of transplant patients, depending on how closely matched the donor is, and is kept in check only by eliminating otherwise useful donor immune cells or by using powerful immune-suppressing drugs.

Studies in mice had shown that the chemotherapy regimens used in HSCT not only wipe out white blood cells (with the intended effect of suppressing the immune system), but also damage the intestinal lining. This breach of the lining allows endotoxin, which is produced by bacteria living in the intestines, to enter the bloodstream. The endotoxin, in turn, provokes an inflammatory response that mobilizes donor immune cells, helping to trigger GVHD.

Levy, in Childrens Division of Infectious Diseases, had long been studying BPI, which naturally blocks and neutralizes endotoxin.(1) BPI is found in neutrophils, the very white blood cells that are virtually wiped out by pre-transplant chemotherapy. Studies in mice had shown that blocking endotoxin reduces the incidence of GVHD after chemotherapy and HSCT.(2)

Intrigued by these findings, Levy and Guinan began to study endotoxin and BPI in human patients undergoing HSCT with pre-transplant chemotherapy. In 2003 they showed, in a study of 57 children, that patients blood endotoxin levels rise markedly within a week of the transplant.(3) And now, in a study of 30 patient:donor pairs to be presented at the ASH meeting, they show that patients undergoing HSCT also have a sharp drop in BPI levels just as their endotoxin levels are rising and that BPI deficiency is associated with a greater likelihood of GVHD.

"BPI is markedly deficient 100 to 1000-fold lower in our transplant patients," says Guinan, associate director of the Center for Clinical and Translational Research at Dana-Farber. "If we can replenish this host defense factor, we might be able to moderate the damaging effects of GVHD."

The multicenter clinical trial, expec
'"/>

Contact: Anna Gonski
anna.gonski@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
11-Dec-2006


Page: 1 2 3

Related biology news :

1. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts
2. Preventing cancer without killing cells
3. Preventing obesity in children -- research highlights physical activity levels
4. Preventing ventilation induced lung injury depends on giving the right number of sighs
5. Preventing bacterial biofilms could help fight TB
6. Preventing fetal exposure to popular acne drug
7. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
8. Size matters: Preventing large mammal extinction
9. Preventing muscle atrophy
10. Undesirable expatriates: Preventing the spread of invasive animals
11. Preventing SCD1 expression prevents obesity

Post Your Comments:
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... Dec. 16, 2014  Automation is fundamentally transforming ... evident than at international borders. Over the past ... have allowed veteran travelers to self process through ... (APC) Kiosks at an increasing number of airports, ... According to Maxine Most , ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
(Date:12/19/2014)... In contrast to traditional LED lights ... colors, Valoya uses proprietary LED technology to incorporate their ... uniformity which is critical in low proximity installations. The ... throughout its lifetime which is up to four times ... "The investment cost was clearly higher when compared to ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
Cached News: